Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.93 |
| ▸ | EED | O75530 | 1/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.93 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.93 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.93 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.93 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.93 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.93 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.93 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18715142 | 0.99 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL18715336 | 0.97 | EZH2 (0.95) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL29350231 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL13276848 | 0.96 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL13277005 | 0.96 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL29361941 | 0.96 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL15313373 | 0.96 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| Tazemetostat SCHEMBL16653521 | 0.96 | EZH2 (0.99) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL31087432 | 0.95 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D | |
| SCHEMBL13276853 | 0.95 | EZH2 (1.00) | EZH2NR1I2EEDABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| EP-4360712-A2 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3943485-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11370781-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220175771-A1 | CANCER TREATMENT MODALITIES | Epizyme, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220160721-A1 | METHODS OF TREATING CANCER | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
| EP-3943485-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943485-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210379076-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-12-09 | — | — | US | disclosed |
| US-8765732-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | disclosed |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | disclosed |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | disclosed |
| US-8410088-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410088-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410088-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. | 2012-10-18 | — | — | US | disclosed |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. | 2012-10-18 | — | — | US | disclosed |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370781-B2 | Combination therapy for treating cancer | EZH2, BMI1, HDAC2 | EZH2 1/4885NR1I2 2153/4885EED 14/4885 |
| US-20220175771-A1 | CANCER TREATMENT MODALITIES | EZH2, BMI1, SUZ12 | EZH2 1/4885NR1I2 2643/4885EED 7/4885 |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885NR1I2 590/4885EED 1667/4885 |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885NR1I2 590/4885EED 1667/4885 |
| US-20220160721-A1 | METHODS OF TREATING CANCER | EZH2, BMI1, EZH1 | EZH2 1/4885NR1I2 3969/4885EED 11/4885 |
| US-20210379076-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885NR1I2 590/4885EED 1667/4885 |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885NR1I2 590/4885EED 1667/4885 |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885NR1I2 590/4885EED 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.